Table 6.
Baseline characteristics of the CardioBBEAT study participants - Therapy
| Characteristic | All patients n = 621 | Usual care n = 319 (51 %) | Monitoring n = 302 (49 %) | p value |
|---|---|---|---|---|
| Medication | ||||
| ACE inhibitor/ARB, n (%) | 577 (93) | 297 (93) | 280 (93) | 0.974 |
| Beta blocker – number/total number (%) | 591/620 (95) | 303/319 (95) | 288/301 (96) | 0.826 |
| MR antagonist, n (%) | 439 (71) | 232 (73) | 207 (69) | 0.291 |
| Diuretics, n (%) | 506 (82) | 255 (80) | 251 (83) | 0.360 |
| Glycosides, n (%) | 95 (15) | 50 (16) | 45 (15) | 0.876 |
| Amiodarone, n (%) | 80 (13) | 48 (15) | 32 (11) | 0.125 |
| Anticoagulation, n (%) | ||||
| Vitamin K antagonist | 231 (37) | 122 (38) | 109 (36) | 0.637 |
| Other | 42 (7) | 24 (8) | 18 (6) | 0.538 |
| Devices, n (%) | ||||
| Pacemaker | 101 (16) | 61 (19) | 40 (13) | 0.061 |
| ICD | 0.280 | |||
| with monitoring | 63 (10) | 31 (10) | 32 (11) | |
| without monitoring | 242 (39) | 134 (42) | 108 (36) | |
| CRT-D | 89 (14) | 40 (13) | 49 (16) | 0.232 |
ACE angiotensin converting enzyme, ARB angiotensin receptor blocker, CRT-D cardiac resynchronization therapy combined with defibrillation ICD implantable cardioverter defibrillator, MR mineralocorticoid receptor